Market Overview

UPDATE: MLV & Co Upgrades XOMA on Valuation

Share:
Related XOMA
Jefferies Downgrades XOMA, Slashes Price Target After Significantly Altering Model
Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases (Zacks)

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh upgraded the rating on XOMA (NASDAQ: XOMA) from Hold to Buy, and reiterated the $7.00 price target.

In the report, MLV & Co noted, “We now upgrade shares of XOMA. Our call is based on 1) valuation and 2) optimism around positive upcoming data from the P3 EYEGUARD-B trial in Behcet's uveitis (an orphan eye condition) for lead asset gevokizumab (gevo) expected sometime mid-year. On positive data, we're expecting ~15-20% of upside to the stock, with potential for add'l upside in the form of two other P3 readouts for gevo expected by year-end (from the EYEGUARD-A/C trials), we feel comfortable taking XOMA now back up to Buy, while maintaining our 1-yr $7 PT.”

XOMA closed on Monday at $3.82.

Latest Ratings for XOMA

DateFirmActionFromTo
Jul 2015JefferiesDowngradesBuyHold
Jun 2015SusquehannaDowngradesPositiveNeutral
May 2015Credit SuisseAssumesNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: Graig C. Suvannavejh MLV & CoAnalyst Color Upgrades Analyst Ratings

 

Related Articles (XOMA)

Get Benzinga's Newsletters